Sanofi mulls the sale of certain drugs

Reuters reports that the French pharmaceutical firm (SNY) is working with Evercore partners to find a buyer for a portfolio of mature drugs that include treatments for high blood pressure and cardio-metabolic diseases.

The businesses, which generate ~$3.7B in annual sales, should fetch between $7B and $8B.

Generic firms or specialty pharma companies are likely acquirers.

Sanofi's initiative is consistent with other members of big pharma who want to shed smaller, less profitable and/or non-core businesses in order to focus on their principal growth drivers.


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs